A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Kuemmel, Sherko; Campone, Mario; Loirat, Delphine; Lopez Lopez, Rafael; Beck, J.; De Laurentiis, Michelino; Im, Seock-Ah; Kim, Sung-Bae; Kwong, Ava; Steger, Guenther; Adelantado, Esther; Duhoux, Francois; Greil, Richard; Kuter, Irene; Lu, Yen-Shen; Tibau, Ariadna; ÖZGÜROĞLU, Mustafa; Scholz, Christian; Singer, Christian; Vega, Estela; Wimberger, Pauline; Zamagni, Claudio; Couillebault, Xuan-Mai; Fan, Liqiong; Guerreiro, Nelson; Mataraza, Jennifer; Sand-Dejmek, Janna; Chan, Arlene

doi:10.1158/1078-0432.ccr-20-3955

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Kuemmel S., Campone M., Loirat D., Lopez Lopez R., Beck J. T., De Laurentiis M., ...More

CLINICAL CANCER RESEARCH, vol.28, no.1, pp.106-115, 2022 (SCI-Expanded)

Publication Type: Article / Article
Volume: 28 Issue: 1
Publication Date: 2022
Doi Number: 10.1158/1078-0432.ccr-20-3955
Journal Name: CLINICAL CANCER RESEARCH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, BIOSIS, Biotechnology Research Abstracts, EMBASE, Gender Studies Database, MEDLINE
Page Numbers: pp.106-115
Istanbul University Affiliated: No

Abstract

Purpose: This phase II study determined the efficacy of lacnotuzumab added to gemcitabine plus carboplatin (gem-carbo) in patients with advanced triple-negative breast cancer (TNBC).